Compare Amylx Pharmaceuticals Inc (AMLX) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Southern Copper Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.28 (market cap $1.98B), while Southern Copper Corp trades at $178.04 (market cap $146.70B). The key difference: Southern Copper Corp is far larger — about 74.1× Amylx Pharmaceuticals Inc's market cap, and Southern Copper Corp pays a 2.27% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SCCO | |
|---|---|---|
Market Cap | $1.98B | $146.70B |
Sector | Health | Basic Materials |
52-Week High | $18.70 | $218.85 |
52-Week Low | $7.64 | $90.54 |
Enterprise Value | $1.70B | $148.75B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SCCO trades at $175.83, up 0.8% on the day, with a neutral technical signal and bearish moving averages. The stock exhibits strong fundamentals, with revenue growing from $10.0B in 2022 to $13.4B in 2025 and net income margin expanding to 34.13%. Recent earnings beats and a $1.00 dividend payment in May 2026 highlight operational strength. However, valuation ratios like a P/E of 29.77 and P/B of 12.45 suggest premium pricing relative to historical norms.
The outlook for SCCO is mixed; robust earnings growth and positive analyst coverage from Zacks (Strong Buy on July 10, 2026) support upside potential, but high valuations and a consensus price target of $151.58 indicate near-term overvaluation risks. Key risks include commodity price volatility and execution challenges in capital expenditures, while institutional sentiment remains cautious with only 10.34% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
